Alnylam
The power of representation, innovation and trust in rare disease clinical trials
By Carol Pitcher-Towner
Alnylam’s RNAi therapeutic vutrisiran recommended by CHMP for rare heart disease
The committee has recommended the drug for both wild type and hereditary ATTR-CM
Alnylam scores EU approval for RNAi drug Givlaari
Company says it will work towards value-based agreements for the drug
Alnylam’s third RNAi drug clears phase 3 trial in rare kidney disease
Plans to file for approval in US and Europe in early 2020
FDA clears Alnylam’s second RNAi drug for rare disease
Second drug in the class to be cleared by regulatory authority
NICE says no to rival Alnylam and Akcea amyliodsis drugs – but deal could be done
Room for manoeuvre after initial rejection
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines